Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors

Japanese Journal of Clinical Oncology

Volumn 37, Issue 1, 2007, Pages 44-48

  Kawada, Kenji ^a   Murakami, Koji ^a   Sato, Takashi ^a   Kojima, Yoshiki ^a   Ebi, Hiromichi ^a   Mukai, Hirofumi ^a   Tahara, Makoto ^a   Shimokata, Kaoru ^b   Minami, Hironobu ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; FDG PET; Lapatinib; Pharmacodynamics; Phase I

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE; LAPATINIB; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SARCOMA; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34447631719     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl116     Document Type: Article

References (22)

1. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34:414-9.
2. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: A method to assess the proliferative activity ot human cancer in vivo Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-81.
3. Cohade C, Wahl RL. PET scanning and measuring the impact of treatment. Cancer J 2002;8:119-34.
4. MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92.
5. Stokkel MP, Draisma A, Pauwels EK. Positron emission tomography is with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol 2001;127:278-85.
6. van der Hiel B, Pauwels EK, Stokkel MP. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa: Therapy response monitoring in breast cancer, lymphoma and gliomas. J Cancer Res Chin Oncol 2001;127:269-77.
7. 8F]-flourodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-82
8. Burris HA, 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible, dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13.
9. Minami H, Nakagawa K, Kawada K, Mukai H, Tahara M, Kurata T, et al. A phase I study of GW572016 in patiets with solid tumors. Proc ASCO 2004;23:3048.
10. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 2001;19:265-72.
11. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8:935-38.
12. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83.
13. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I. et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997:15:3266-74.
14. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
15. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
16. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2005;22:3238-47.
17. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY43-9006) in patients with advanced renal cell carcinoma. Proc ASCO 2005;41:4510.
18. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
19. Christian W, Arash S, Ingo M. Effects of PKI-166 oil A-431 vulvar carcinoma in SCID mice assessed with microPET using 18F-FLT and 18F-FDG. Proc AACR 2003;94:6190.
20. Keyes JW, Jr. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
21. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7.
22. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: Reproducibility of rquantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995;196:167-73.